Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, Robert J Vanner, David F Schaeffer, Aly Karsan, Howard Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, Stephen K Chia, Hagen F Kennecke, Derek J Jonker, Eric X Chen, Daniel J Renouf, Chris J O'Callaghan, Jonathan M Loree
{"title":"不确定潜能克隆造血（CHIP）及其与实体肿瘤患者治疗结果和不良事件的关联","authors":"Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, Robert J Vanner, David F Schaeffer, Aly Karsan, Howard Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, Stephen K Chia, Hagen F Kennecke, Derek J Jonker, Eric X Chen, Daniel J Renouf, Chris J O'Callaghan, Jonathan M Loree","doi":"10.1158/2767-9764.CRC-24-0522","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>Liquid biopsy is increasingly being used in oncology for tumor molecular characterization. CHIP is a common incidental finding in cfDNA, and its prevalence increases with age. This study builds on growing evidence of common CHIP variants in patients with solid tumors. The results suggest a possible clinical impact of CHIP on treatment outcomes from immunotherapy or chemotherapy. This may have implications for treatment selection for patients with solid tumors.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"66-73"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11713863/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors.\",\"authors\":\"Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, Robert J Vanner, David F Schaeffer, Aly Karsan, Howard Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, Stephen K Chia, Hagen F Kennecke, Derek J Jonker, Eric X Chen, Daniel J Renouf, Chris J O'Callaghan, Jonathan M Loree\",\"doi\":\"10.1158/2767-9764.CRC-24-0522\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Significance: </strong>Liquid biopsy is increasingly being used in oncology for tumor molecular characterization. CHIP is a common incidental finding in cfDNA, and its prevalence increases with age. This study builds on growing evidence of common CHIP variants in patients with solid tumors. The results suggest a possible clinical impact of CHIP on treatment outcomes from immunotherapy or chemotherapy. This may have implications for treatment selection for patients with solid tumors.</p>\",\"PeriodicalId\":72516,\"journal\":{\"name\":\"Cancer research communications\",\"volume\":\" \",\"pages\":\"66-73\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11713863/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2767-9764.CRC-24-0522\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0522","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors.
Significance: Liquid biopsy is increasingly being used in oncology for tumor molecular characterization. CHIP is a common incidental finding in cfDNA, and its prevalence increases with age. This study builds on growing evidence of common CHIP variants in patients with solid tumors. The results suggest a possible clinical impact of CHIP on treatment outcomes from immunotherapy or chemotherapy. This may have implications for treatment selection for patients with solid tumors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
